Login to Your Account

Protaffin's Lung Disease Drug PA401 Enters Clinical Testing

By Nuala Moran
Staff Writer

Thursday, July 5, 2012
LONDON – The first biologic drug targeting a cell-surface sugar has entered the clinic, with the Phase I trial of Protaffin AG's interleukin-8 (IL-8) decoy PA401 getting under way in the UK.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription